Loading clinical trials...
Loading clinical trials...
Novel Metaphor Processing Among Schizophrenic Patients - Magnetoencephalographic (MEG) Evidence
The aim of this research is to investigate the neurolinguistic mechanisms underlying thought disorders among schizophrenic patients. In particular, it will investigate the neurolinguistic basis for loose association - a phenomena which this population is characterized by. Several researchers have previously suggested that loose associations among schizophrenic patients relate to a lack of inhibition in the automatic spread of activation mechanisms within semantic networks (e.g., Soriano, Jimenez, Roman, \& Bajo, 2008). This research focuses on the relationship between I. the left-right hemisphere dynamic and II. semantic processing, among schizophrenic patients. The research follows Jung-Beeman's (2005) model which relates semantic associations, activation and inhibition processes to the functioning of the two cerebral hemispheres. Previous research suggests that, when compared to the neurotypical population, people with schizophrenia show a less defined - or even reversed - hemispheric lateralization pattern for semantic processing. This is linked to an impairment in language function in the left hemisphere, and to a language functions shift from left to right hemisphere (e.g., Crow, 1997). The investigators assume that this unique lateralization pattern may cause a change in balance in the semantic activation and inhibition system among schizophrenic patients. As stated, one of the linguistic models that predicts how reduced left hemisphere dominancy will influence linguistic functioning is Jung-Beeman's (2005) bilateral model for language understanding. According to this model, the left hemisphere specializes in precise and fine semantic processing, while the right hemisphere specializes in coarse and abstract semantic processing. Building upon this distinction, our assumption is that schizophrenic patients experience a difficulty in fine semantic processing which is caused by functional impairment in the left hemisphere. It is our further assumption that coarse semantic processing - located in the right hemisphere - is relatively unimpaired. This change in the balance between the two processes may have direct implications on the associative semantic network among schizophrenic patients. In order to test this hypothesis, the current research will make use of a specific language expression type which involves fine and coarse semantic processing, and for which there is evidence for crucial right hemisphere involvement: novel metaphor processing. 10-20 adult schizophrenic patients will be presented with four different types of two word expressions: literal; conventional metaphor; novel metaphor and unrelated. The patients will have to decide as quickly and accurately as possible if the expression is meaningful or meaningless while their brain activity is recorded by a Magnetoencephalographic (MEG) device (which combines a high temporal resolution with the ability to localize the activity). Therefore, our main hypothesis is that schizophrenic patients will show a bilateral brain activity pattern when conducting semantic decisions, and that this pattern will be related to improved reaction times and accuracy when presented with novel metaphors than when presented with other types of expressions.
Age
18 - 60 years
Sex
ALL
Healthy Volunteers
Yes
shalvata MHC
Hod HaSharon, Israel
Start Date
April 1, 2011
Primary Completion Date
December 1, 2011
Completion Date
December 1, 2011
Last Updated
March 8, 2012
30
ACTUAL participants
Magnetoencephalograph (MEG)
DEVICE
Lead Sponsor
Shalvata Mental Health Center
NCT07455929
NCT06740383
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions